Laetitia Gerlier1, Mark Lamotte2, Sofia Dos Santos Mendes3, Oliver Damm4, Markus Schwehm5, Martin Eichner6,7. 1. IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium. LGerlier@be.imshealth.com. 2. IMS Health Real-World Evidence Solutions, Corporate Village, Davos Building, Da Vincilaan 7, 1935, Zaventem, Belgium. 3. S.A. AstraZeneca N.V., Uccle, Belgium. 4. Bielefeld University, Bielefeld, Germany. 5. ExploSYS GmbH, Leinfelden-Echterdingen, Germany. 6. Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany. 7. Epimos GmbH, Dusslingen, Germany.
Abstract
OBJECTIVES: Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. METHODS: We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R 0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). RESULTS: Model calibration yielded R 0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. CONCLUSIONS: The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
OBJECTIVES: Our objectives were to estimate the public health outcomes of vaccinating Belgian children using an intranasal tetravalent live-attenuated influenza vaccine (QLAIV) combined with current coverage of high-risk/elderly individuals using the trivalent inactivated vaccine. METHODS: We used a deterministic, age-structured, dynamic model to simulate seasonal influenza transmission in the Belgian population under the current coverage or after extending vaccination with QLAIV to healthy children aged 2-17 years. Differential equations describe demographic changes, exposure to infectious individuals, infection recovery, and immunity dynamics. The basic reproduction number (R 0) was calibrated to the observed number of influenza doctor visits/year. Vaccine efficacy was 80 % (live-attenuated) and 59-68 % (inactivated). The 10-year incidence of symptomatic influenza was calculated with different coverage scenarios (add-on to current coverage). RESULTS: Model calibration yielded R 0 = 1.1. QLAIV coverage of 75 % of those aged 2-17 years averted 374,000 symptomatic cases/year (57 % of the current number), 244,000 of which were among adults (indirect effect). Vaccinating 75 % of those aged 2-11 years and 50 % of those aged 12-17 years averted 333,200 cases/year (213,000 adult cases/year). Vaccinating only healthy children aged 2-5 years generated direct protection but limited indirect protection, even with 90 % coverage (40,800 averted adult cases/year; -8.4 %). Targeting all children averted twice as many high-risk cases as targeting high-risk children only (8485 vs. 4965/year with 75 % coverage). Sensitivity analyses showed the robustness of results. CONCLUSIONS: The model highlights the direct and indirect protection benefits when vaccinating healthy children with QLAIV in Belgium. Policies targeting only high-risk individuals or the youngest provide limited herd protection, as school-age children are important influenza vectors in the community.
Authors: Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Beverly M Snively; Cynthia K Suerken; Caroline B Hall; Geoffrey A Weinberg; Sandra S Chaves; Yuwei Zhu; Monica M McNeal; Carolyn B Bridges Journal: Pediatrics Date: 2013-01-06 Impact factor: 7.124
Authors: Timo Vesikari; Markus Knuf; Peter Wutzler; Aino Karvonen; Dorothee Kieninger-Baum; Heinz-Josef Schmitt; Frank Baehner; Astrid Borkowski; Theodore F Tsai; Ralf Clemens Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Maria Yui Kwan Chow; Jiehui Kevin Yin; Leon Heron; Angela Morrow; Alexa Dierig; Robert Booy; Julie Leask Journal: Qual Life Res Date: 2013-12-27 Impact factor: 4.147
Authors: Simon de Lusignan; Ray Borrow; Manasa Tripathy; Ezra Linley; Maria Zambon; Katja Hoschler; Filipa Ferreira; Nick Andrews; Ivelina Yonova; Mariya Hriskova; Imran Rafi; Richard Pebody Journal: BMJ Open Date: 2019-03-08 Impact factor: 2.692